We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.25%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$398M
AUM Growth
+$20.8M
Cap. Flow
+$11.1M
Cap. Flow %
2.8%
Top 10 Hldgs %
51.36%
Holding
92
New
12
Increased
23
Reduced
18
Closed
5

Top Buys

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$4.8M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.99M
3
AXGN icon
Axogen
AXGN
+$3.98M
4
ACET icon
Adicet Bio
ACET
+$3.83M
5
BMEA icon
Biomea Fusion
BMEA
+$3.32M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11.8M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$3.81M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$2.74M
4
AFMD
Affimed
AFMD
+$2.43M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$1.83M

Sector Composition

Rank Sector Weight
1 Healthcare 94.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFI
76
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$531K 0.13%
236,160
– –
PHVS icon
77
Pharvaris
PHVS
$2.44B
$528K 0.13%
36,720
+1,646
+5% +$25.7K
ADAP
78
DELISTED
Adaptimmune Therapeutics
ADAP
$511K 0.13%
+136,266
New +$620K
INGN icon
79
Inogen
INGN
$164M
$510K 0.13%
15,000
– –
BOLT icon
80
Bolt Biotherapeutics
BOLT
$7.78M
$490K 0.12%
5,000
– –
MDGL icon
81
Madrigal Pharmaceuticals
MDGL
$11.8B
$475K 0.12%
5,600
– –
SRGA
82
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$415K 0.1%
19,324
– –
ANNX icon
83
Annexon
ANNX
$886M
$354K 0.09%
30,796
+7,500
+32% +$121K
GNFT
84
DELISTED
Genfit
GNFT
$302K 0.08%
60,448
-128,101
-68% -$480K
LCTX icon
85
Lineage Cell Therapeutics
LCTX
$274M
$196K 0.05%
+80,000
New +$187K
IFRX icon
86
InflaRx
IFRX
$271M
– –
-600,000
Closed -$1.55M
NTBL
87
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
– –
-1,571
Closed -$113K
ALPN
88
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-111,501
Closed -$1.19M
DRNA
89
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-587,456
Closed -$11.8M
KDMN
90
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-314,561
Closed -$2.74M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, DAFNA Capital Management held 92 positions worth $398M, up 5.5% from $377M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management's Q4 2021 filing shows 12 new, 23 increased, 18 reduced and 5 closed positions. Its largest new stake was Axogen: 332,103 shares worth $3.11M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $11.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier.

  • DAFNA Capital Management's largest Q4 2021 buy was Axogen: 332,103 shares worth $3.11M.
  • DAFNA Capital Management added most to Cymabay Therapeutics in Q4 2021, an estimated $4.8M increase.
  • DAFNA Capital Management's biggest Q4 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $3.81M.
  • DAFNA Capital Management fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $11.8M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $398M portfolio in Q4 2021.
  • DAFNA Capital Management opened 12 new positions and closed 5 in Q4 2021.
  • DAFNA Capital Management's portfolio value rose 5.5% quarter-over-quarter to $398M.

Based on DAFNA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.